IMA

SCHEDULE 13D - ImageneBio, Inc. (0001835579) (Subject)

3 - ImageneBio, Inc. (0001835579) (Issuer)

3 - ImageneBio, Inc. (0001835579) (Issuer)

4 - ImageneBio, Inc. (0001835579) (Issuer)

4 - ImageneBio, Inc. (0001835579) (Issuer)

424B3 - ImageneBio, Inc. (0001835579) (Filer)

8-K - ImageneBio, Inc. (0001835579) (Filer)

Private placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for the ongoing program in moderate-to-severe atopic dermatitis IMG-007 is the lead receptor-targeting, non-depleting OX40 antagonist in active clinical development  SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA)("Imagene" or the "Company") today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million

EFFECT - ImageneBio, Inc. (0001835579) (Filer)

POS AM - ImageneBio, Inc. (0001835579) (Filer)

4 - ImageneBio, Inc. (0001835579) (Issuer)

8-K - ImageneBio, Inc. (0001835579) (Filer)

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that on March 16, 2026 the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") granted equity awards to two newly hired employees in the form of restricted stock units ("RSUs") and non-qualified stock options ("NSOs") for an aggregate of 38,442 RSUs and 43,000 NSOs as an inducement material to their acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The employment inducement awards were granted under the Company's 2025 Inducement Plan. Each NSO has an exercise price equal to $6.20 per share,

S-8 - ImageneBio, Inc. (0001835579) (Filer)

10-K - ImageneBio, Inc. (0001835579) (Filer)

8-K - ImageneBio, Inc. (0001835579) (Filer)

SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a company update. Company Highlights The IMG-007 Phase 2b ADAPTIVE trial in adults with moderate-to-severe atopic dermatitis (AD) is ongoing at North American sites; the study began enrolling in mid-2025 with topline data expected in 2027. A recent blinded safety review showed a favorable emerging tolerability profile consistent with previous IMG-007 patient experience.The Company has submitted a protocol amendment intended to expand the number and exposure range of dosing regim

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida. Fireside Date: Tuesday, March 10Time: 3:00pm ESTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated clinical profiles. The Company's program, IMG-007, is a receptor targe

3 - ImageneBio, Inc. (0001835579) (Issuer)

424B3 - ImageneBio, Inc. (0001835579) (Filer)

8-K - ImageneBio, Inc. (0001835579) (Filer)

SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)

Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

4 - ImageneBio, Inc. (0001835579) (Issuer)

4 - ImageneBio, Inc. (0001835579) (Issuer)